BioRestorative Therapies (BRTX) Depreciation & Amortization (CF) (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Depreciation & Amortization (CF) came in at $52836.0 in Q4 2025, up 4.9% YoY from $50369.0 in Q4 2024, and little changed on a QoQ basis from $52620.0 in Q3 2025.
BioRestorative Therapies (BRTX) Depreciation & Amortization (CF) (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Depreciation & Amortization (CF) data on file, last reported at $52836.0 in Q4 2025.
- Quarterly Depreciation & Amortization (CF) rose 4.9% year-over-year to $52836.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $209985.0 (up 11.07% YoY) and the FY2025 annual result came in at $209985.0, up 11.07% from the prior year.
- Depreciation & Amortization (CF) held at $52836.0 in Q4 2025, from $52620.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $52836.0 in Q4 2025 to a low of $21496.0 in Q4 2021.
- A 5-year average of $38721.4 and a median of $41835.5 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) sank 44.7% — and 2023, when it surged 51.29%.
- Tracing BRTX's Depreciation & Amortization (CF) over 5 years: stood at $21496.0 in 2021, then soared by 47.91% to $31794.0 in 2022, then surged by 34.34% to $42713.0 in 2023, then climbed by 17.92% to $50369.0 in 2024, then increased by 4.9% to $52836.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $52836.0 (Q4 2025), $52620.0 (Q3 2025), and $52748.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.02 Mn | 17,964.00 | 52,836.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 52,836.00 |
| Dec 31, 2025 | 52,836.00 |
| Sep 30, 2025 | 52,620.00 |
| Sep 30, 2025 | 52,620.00 |
| Jun 30, 2025 | 52,748.00 |
| Jun 30, 2025 | 52,748.00 |
| Mar 31, 2025 | 51,781.00 |
| Mar 31, 2025 | 51,781.00 |
| Dec 31, 2024 | 50,369.00 |
| Dec 31, 2024 | 50,369.00 |
| Sep 30, 2024 | 48,269.00 |
| Sep 30, 2024 | 48,269.00 |
| Jun 30, 2024 | 47,705.00 |
| Jun 30, 2024 | 47,705.00 |
| Mar 31, 2024 | 42,713.00 |
| Mar 31, 2024 | 42,713.00 |
| Dec 31, 2023 | 42,713.00 |
| Dec 31, 2023 | 42,713.00 |
| Sep 30, 2023 | 42,145.00 |
| Sep 30, 2023 | 42,145.00 |